Agenus Announces New Responses for AGEN1181
February 09, 2021 08:45 ET
|
Agenus Inc.
6 total confirmed objective clinical responses in colon, ovarian, and endometrial cancersNo complement-mediated toxicities reported LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc....
Agenus Announces Positive Preliminary Results of iNKT Cell Therapy Trial in COVID-19
February 04, 2021 08:30 ET
|
Agenus Inc.
3 out of 4 intubated patients were discharged after treatment2 out of 4 patients were extubated within 24 hours of dosing LEXINGTON, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ:...
Agenus Enters into Clinical Collaboration with Nelum for Zalifrelimab Combination
January 26, 2021 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and...
Agenus to Participate in B. Riley Securities' Oncology Investor Conference
January 19, 2021 12:09 ET
|
Agenus Inc.
LEXINGTON, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and...
Completion of Balstilimab BLA Filing Extended To 1H2021
December 03, 2020 07:45 ET
|
Agenus Inc.
LEXINGTON, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline which includes checkpoint antibodies, cell therapies, adjuvants, and...
Agenus Launches Phase 2 Trial Expansion in Colon Cancer for AGEN1181 in Combination with Balstilimab
December 01, 2020 08:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline which includes checkpoint antibodies, cell therapies, adjuvants, and...
Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference
November 25, 2020 13:28 ET
|
Agenus Inc.
LEXINGTON, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and...
Agenus to Participate in Fireside Chat at the Jefferies 2020 Virtual London Healthcare Conference
November 16, 2020 19:04 ET
|
Agenus Inc.
LEXINGTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and...
Agenus and Dr. Steven O’Day to Participate in Webcast Hosted by William Blair on AGEN1181 and SITC Data
November 13, 2020 14:43 ET
|
Agenus Inc.
LEXINGTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and...
Agenus and Dr. Steven O’Day to Participate in Panels at the Virtual SITC 2020 Immuno-Oncology Event Hosted by B. Riley
November 12, 2020 09:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and...